COVID-19 Impact on Global Central Nervous System Biomarkers Market Size, Status and Forecast 2020-2026
![](/report_cover/6975/covid-19-impact-on-global-central-nervous-system-biomarkers-market-size-status-n-forecast-2020-2026_en.gif)
With extensive ongoing development in personalized medicines and the application of biomarkers in diagnosis, the complexity of the central nervous system paves way for the development of biomarkers to enhance early diagnosis of neurological disorders such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, and other neurological conditions.
Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Central Nervous System Biomarkers market in 2020.
COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.
The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.
This report also analyses the impact of Coronavirus COVID-19 on the Central Nervous System Biomarkers industry.
Based on our recent survey, we have several different scenarios about the Central Nervous System Biomarkers YoY growth rate for 2020. The probable scenario is expected to grow by a xx% in 2020 and the revenue will be xx in 2020 from US$ 3743.3 million in 2019. The market size of Central Nervous System Biomarkers will reach xx in 2026, with a CAGR of xx% from 2020 to 2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Central Nervous System Biomarkers market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Central Nervous System Biomarkers market in terms of revenue.
Players, stakeholders, and other participants in the global Central Nervous System Biomarkers market will be able to gain the upper hand as they use the report as a powerful resource. For this version of the report, the segmental analysis focuses on revenue and forecast by each application segment in terms of revenue and forecast by each type segment in terms of revenue for the period 2015-2026.
Regional and Country-level Analysis
The report offers an exhaustive geographical analysis of the global Central Nervous System Biomarkers market, covering important regions, viz, North America, Europe, China, Japan, Southeast Asia, India and Central & South America. It also covers key countries (regions), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by each application segment in terms of revenue for the period 2015-2026.
Competition Analysis
In the competitive analysis section of the report, leading as well as prominent players of the global Central Nervous System Biomarkers market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Central Nervous System Biomarkers market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Central Nervous System Biomarkers market.
The following players are covered in this report:
Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Central Nervous System Biomarkers market in 2020.
COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.
The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.
This report also analyses the impact of Coronavirus COVID-19 on the Central Nervous System Biomarkers industry.
Based on our recent survey, we have several different scenarios about the Central Nervous System Biomarkers YoY growth rate for 2020. The probable scenario is expected to grow by a xx% in 2020 and the revenue will be xx in 2020 from US$ 3743.3 million in 2019. The market size of Central Nervous System Biomarkers will reach xx in 2026, with a CAGR of xx% from 2020 to 2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Central Nervous System Biomarkers market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Central Nervous System Biomarkers market in terms of revenue.
Players, stakeholders, and other participants in the global Central Nervous System Biomarkers market will be able to gain the upper hand as they use the report as a powerful resource. For this version of the report, the segmental analysis focuses on revenue and forecast by each application segment in terms of revenue and forecast by each type segment in terms of revenue for the period 2015-2026.
Regional and Country-level Analysis
The report offers an exhaustive geographical analysis of the global Central Nervous System Biomarkers market, covering important regions, viz, North America, Europe, China, Japan, Southeast Asia, India and Central & South America. It also covers key countries (regions), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by each application segment in terms of revenue for the period 2015-2026.
Competition Analysis
In the competitive analysis section of the report, leading as well as prominent players of the global Central Nervous System Biomarkers market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Central Nervous System Biomarkers market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Central Nervous System Biomarkers market.
The following players are covered in this report:
- Merck
- Takeda Pharmaceutical
- Thermo Fisher Scientific
- Avacta Group
- Diagenic Asa
- Banyan Biomarkers
- Eli Lilly
- Pfizer
- Alseres Pharmaceuticals
- Acumen pharmaceuticals
- EKF Diagnostics
- Abiant
- Myriad RBM
- Aposense
- Safety Biomarker
- Efficacy Biomarker
- Validation Biomarker
- Other
- Hospitals
- Clinics
- Others
1 REPORT OVERVIEW
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Central Nervous System Biomarkers Revenue
1.4 Market Analysis by Type
1.4.1 Global Central Nervous System Biomarkers Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Safety Biomarker
1.4.3 Efficacy Biomarker
1.4.4 Validation Biomarker
1.4.5 Other
1.5 Market by Application
1.5.1 Global Central Nervous System Biomarkers Market Share by Application: 2020 VS 2026
1.5.2 Hospitals
1.5.3 Clinics
1.5.4 Others
1.6 Coronavirus Disease 2019 (Covid-19): Central Nervous System Biomarkers Industry Impact
1.6.1 How the Covid-19 is Affecting the Central Nervous System Biomarkers Industry
1.6.1.1 Central Nervous System Biomarkers Business Impact Assessment - Covid-19
1.6.1.2 Supply Chain Challenges
1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
1.6.2 Market Trends and Central Nervous System Biomarkers Potential Opportunities in the COVID-19 Landscape
1.6.3 Measures / Proposal against Covid-19
1.6.3.1 Government Measures to Combat Covid-19 Impact
1.6.3.2 Proposal for Central Nervous System Biomarkers Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered
2 GLOBAL GROWTH TRENDS BY REGIONS
2.1 Central Nervous System Biomarkers Market Perspective (2015-2026)
2.2 Central Nervous System Biomarkers Growth Trends by Regions
2.2.1 Central Nervous System Biomarkers Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Central Nervous System Biomarkers Historic Market Share by Regions (2015-2020)
2.2.3 Central Nervous System Biomarkers Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Central Nervous System Biomarkers Market Growth Strategy
2.3.6 Primary Interviews with Key Central Nervous System Biomarkers Players (Opinion Leaders)
3 COMPETITION LANDSCAPE BY KEY PLAYERS
3.1 Global Top Central Nervous System Biomarkers Players by Market Size
3.1.1 Global Top Central Nervous System Biomarkers Players by Revenue (2015-2020)
3.1.2 Global Central Nervous System Biomarkers Revenue Market Share by Players (2015-2020)
3.1.3 Global Central Nervous System Biomarkers Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Central Nervous System Biomarkers Market Concentration Ratio
3.2.1 Global Central Nervous System Biomarkers Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Central Nervous System Biomarkers Revenue in 2019
3.3 Central Nervous System Biomarkers Key Players Head office and Area Served
3.4 Key Players Central Nervous System Biomarkers Product Solution and Service
3.5 Date of Enter into Central Nervous System Biomarkers Market
3.6 Mergers & Acquisitions, Expansion Plans
4 BREAKDOWN DATA BY TYPE (2015-2026)
4.1 Global Central Nervous System Biomarkers Historic Market Size by Type (2015-2020)
4.2 Global Central Nervous System Biomarkers Forecasted Market Size by Type (2021-2026)
5 CENTRAL NERVOUS SYSTEM BIOMARKERS BREAKDOWN DATA BY APPLICATION (2015-2026)
5.1 Global Central Nervous System Biomarkers Market Size by Application (2015-2020)
5.2 Global Central Nervous System Biomarkers Forecasted Market Size by Application (2021-2026)
6 NORTH AMERICA
6.1 North America Central Nervous System Biomarkers Market Size (2015-2020)
6.2 Central Nervous System Biomarkers Key Players in North America (2019-2020)
6.3 North America Central Nervous System Biomarkers Market Size by Type (2015-2020)
6.4 North America Central Nervous System Biomarkers Market Size by Application (2015-2020)
7 EUROPE
7.1 Europe Central Nervous System Biomarkers Market Size (2015-2020)
7.2 Central Nervous System Biomarkers Key Players in Europe (2019-2020)
7.3 Europe Central Nervous System Biomarkers Market Size by Type (2015-2020)
7.4 Europe Central Nervous System Biomarkers Market Size by Application (2015-2020)
8 CHINA
8.1 China Central Nervous System Biomarkers Market Size (2015-2020)
8.2 Central Nervous System Biomarkers Key Players in China (2019-2020)
8.3 China Central Nervous System Biomarkers Market Size by Type (2015-2020)
8.4 China Central Nervous System Biomarkers Market Size by Application (2015-2020)
9 JAPAN
9.1 Japan Central Nervous System Biomarkers Market Size (2015-2020)
9.2 Central Nervous System Biomarkers Key Players in Japan (2019-2020)
9.3 Japan Central Nervous System Biomarkers Market Size by Type (2015-2020)
9.4 Japan Central Nervous System Biomarkers Market Size by Application (2015-2020)
10 SOUTHEAST ASIA
10.1 Southeast Asia Central Nervous System Biomarkers Market Size (2015-2020)
10.2 Central Nervous System Biomarkers Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Central Nervous System Biomarkers Market Size by Type (2015-2020)
10.4 Southeast Asia Central Nervous System Biomarkers Market Size by Application (2015-2020)
11 INDIA
11.1 India Central Nervous System Biomarkers Market Size (2015-2020)
11.2 Central Nervous System Biomarkers Key Players in India (2019-2020)
11.3 India Central Nervous System Biomarkers Market Size by Type (2015-2020)
11.4 India Central Nervous System Biomarkers Market Size by Application (2015-2020)
12 CENTRAL & SOUTH AMERICA
12.1 Central & South America Central Nervous System Biomarkers Market Size (2015-2020)
12.2 Central Nervous System Biomarkers Key Players in Central & South America (2019-2020)
12.3 Central & South America Central Nervous System Biomarkers Market Size by Type (2015-2020)
12.4 Central & South America Central Nervous System Biomarkers Market Size by Application (2015-2020)
13 KEY PLAYERS PROFILES
13.1 Merck
13.1.1 Merck Company Details
13.1.2 Merck Business Overview and Its Total Revenue
13.1.3 Merck Central Nervous System Biomarkers Introduction
13.1.4 Merck Revenue in Central Nervous System Biomarkers Business (2015-2020))
13.1.5 Merck Recent Development
13.2 Takeda Pharmaceutical
13.2.1 Takeda Pharmaceutical Company Details
13.2.2 Takeda Pharmaceutical Business Overview and Its Total Revenue
13.2.3 Takeda Pharmaceutical Central Nervous System Biomarkers Introduction
13.2.4 Takeda Pharmaceutical Revenue in Central Nervous System Biomarkers Business (2015-2020)
13.2.5 Takeda Pharmaceutical Recent Development
13.3 Thermo Fisher Scientific
13.3.1 Thermo Fisher Scientific Company Details
13.3.2 Thermo Fisher Scientific Business Overview and Its Total Revenue
13.3.3 Thermo Fisher Scientific Central Nervous System Biomarkers Introduction
13.3.4 Thermo Fisher Scientific Revenue in Central Nervous System Biomarkers Business (2015-2020)
13.3.5 Thermo Fisher Scientific Recent Development
13.4 Avacta Group
13.4.1 Avacta Group Company Details
13.4.2 Avacta Group Business Overview and Its Total Revenue
13.4.3 Avacta Group Central Nervous System Biomarkers Introduction
13.4.4 Avacta Group Revenue in Central Nervous System Biomarkers Business (2015-2020)
13.4.5 Avacta Group Recent Development
13.5 Diagenic Asa
13.5.1 Diagenic Asa Company Details
13.5.2 Diagenic Asa Business Overview and Its Total Revenue
13.5.3 Diagenic Asa Central Nervous System Biomarkers Introduction
13.5.4 Diagenic Asa Revenue in Central Nervous System Biomarkers Business (2015-2020)
13.5.5 Diagenic Asa Recent Development
13.6 Banyan Biomarkers
13.6.1 Banyan Biomarkers Company Details
13.6.2 Banyan Biomarkers Business Overview and Its Total Revenue
13.6.3 Banyan Biomarkers Central Nervous System Biomarkers Introduction
13.6.4 Banyan Biomarkers Revenue in Central Nervous System Biomarkers Business (2015-2020)
13.6.5 Banyan Biomarkers Recent Development
13.7 Eli Lilly
13.7.1 Eli Lilly Company Details
13.7.2 Eli Lilly Business Overview and Its Total Revenue
13.7.3 Eli Lilly Central Nervous System Biomarkers Introduction
13.7.4 Eli Lilly Revenue in Central Nervous System Biomarkers Business (2015-2020)
13.7.5 Eli Lilly Recent Development
13.8 Pfizer
13.8.1 Pfizer Company Details
13.8.2 Pfizer Business Overview and Its Total Revenue
13.8.3 Pfizer Central Nervous System Biomarkers Introduction
13.8.4 Pfizer Revenue in Central Nervous System Biomarkers Business (2015-2020)
13.8.5 Pfizer Recent Development
13.9 Alseres Pharmaceuticals
13.9.1 Alseres Pharmaceuticals Company Details
13.9.2 Alseres Pharmaceuticals Business Overview and Its Total Revenue
13.9.3 Alseres Pharmaceuticals Central Nervous System Biomarkers Introduction
13.9.4 Alseres Pharmaceuticals Revenue in Central Nervous System Biomarkers Business (2015-2020)
13.9.5 Alseres Pharmaceuticals Recent Development
13.10 Acumen pharmaceuticals
13.10.1 Acumen pharmaceuticals Company Details
13.10.2 Acumen pharmaceuticals Business Overview and Its Total Revenue
13.10.3 Acumen pharmaceuticals Central Nervous System Biomarkers Introduction
13.10.4 Acumen pharmaceuticals Revenue in Central Nervous System Biomarkers Business (2015-2020)
13.10.5 Acumen pharmaceuticals Recent Development
13.11 EKF Diagnostics
10.11.1 EKF Diagnostics Company Details
10.11.2 EKF Diagnostics Business Overview and Its Total Revenue
10.11.3 EKF Diagnostics Central Nervous System Biomarkers Introduction
10.11.4 EKF Diagnostics Revenue in Central Nervous System Biomarkers Business (2015-2020)
10.11.5 EKF Diagnostics Recent Development
13.12 Abiant
10.12.1 Abiant Company Details
10.12.2 Abiant Business Overview and Its Total Revenue
10.12.3 Abiant Central Nervous System Biomarkers Introduction
10.12.4 Abiant Revenue in Central Nervous System Biomarkers Business (2015-2020)
10.12.5 Abiant Recent Development
13.13 Myriad RBM
10.13.1 Myriad RBM Company Details
10.13.2 Myriad RBM Business Overview and Its Total Revenue
10.13.3 Myriad RBM Central Nervous System Biomarkers Introduction
10.13.4 Myriad RBM Revenue in Central Nervous System Biomarkers Business (2015-2020)
10.13.5 Myriad RBM Recent Development
13.14 Aposense
10.14.1 Aposense Company Details
10.14.2 Aposense Business Overview and Its Total Revenue
10.14.3 Aposense Central Nervous System Biomarkers Introduction
10.14.4 Aposense Revenue in Central Nervous System Biomarkers Business (2015-2020)
10.14.5 Aposense Recent Development
14 ANALYST'S VIEWPOINTS/CONCLUSIONS
15 APPENDIX
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Central Nervous System Biomarkers Revenue
1.4 Market Analysis by Type
1.4.1 Global Central Nervous System Biomarkers Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Safety Biomarker
1.4.3 Efficacy Biomarker
1.4.4 Validation Biomarker
1.4.5 Other
1.5 Market by Application
1.5.1 Global Central Nervous System Biomarkers Market Share by Application: 2020 VS 2026
1.5.2 Hospitals
1.5.3 Clinics
1.5.4 Others
1.6 Coronavirus Disease 2019 (Covid-19): Central Nervous System Biomarkers Industry Impact
1.6.1 How the Covid-19 is Affecting the Central Nervous System Biomarkers Industry
1.6.1.1 Central Nervous System Biomarkers Business Impact Assessment - Covid-19
1.6.1.2 Supply Chain Challenges
1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
1.6.2 Market Trends and Central Nervous System Biomarkers Potential Opportunities in the COVID-19 Landscape
1.6.3 Measures / Proposal against Covid-19
1.6.3.1 Government Measures to Combat Covid-19 Impact
1.6.3.2 Proposal for Central Nervous System Biomarkers Players to Combat Covid-19 Impact
1.7 Study Objectives
1.8 Years Considered
2 GLOBAL GROWTH TRENDS BY REGIONS
2.1 Central Nervous System Biomarkers Market Perspective (2015-2026)
2.2 Central Nervous System Biomarkers Growth Trends by Regions
2.2.1 Central Nervous System Biomarkers Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Central Nervous System Biomarkers Historic Market Share by Regions (2015-2020)
2.2.3 Central Nervous System Biomarkers Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Central Nervous System Biomarkers Market Growth Strategy
2.3.6 Primary Interviews with Key Central Nervous System Biomarkers Players (Opinion Leaders)
3 COMPETITION LANDSCAPE BY KEY PLAYERS
3.1 Global Top Central Nervous System Biomarkers Players by Market Size
3.1.1 Global Top Central Nervous System Biomarkers Players by Revenue (2015-2020)
3.1.2 Global Central Nervous System Biomarkers Revenue Market Share by Players (2015-2020)
3.1.3 Global Central Nervous System Biomarkers Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Central Nervous System Biomarkers Market Concentration Ratio
3.2.1 Global Central Nervous System Biomarkers Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Central Nervous System Biomarkers Revenue in 2019
3.3 Central Nervous System Biomarkers Key Players Head office and Area Served
3.4 Key Players Central Nervous System Biomarkers Product Solution and Service
3.5 Date of Enter into Central Nervous System Biomarkers Market
3.6 Mergers & Acquisitions, Expansion Plans
4 BREAKDOWN DATA BY TYPE (2015-2026)
4.1 Global Central Nervous System Biomarkers Historic Market Size by Type (2015-2020)
4.2 Global Central Nervous System Biomarkers Forecasted Market Size by Type (2021-2026)
5 CENTRAL NERVOUS SYSTEM BIOMARKERS BREAKDOWN DATA BY APPLICATION (2015-2026)
5.1 Global Central Nervous System Biomarkers Market Size by Application (2015-2020)
5.2 Global Central Nervous System Biomarkers Forecasted Market Size by Application (2021-2026)
6 NORTH AMERICA
6.1 North America Central Nervous System Biomarkers Market Size (2015-2020)
6.2 Central Nervous System Biomarkers Key Players in North America (2019-2020)
6.3 North America Central Nervous System Biomarkers Market Size by Type (2015-2020)
6.4 North America Central Nervous System Biomarkers Market Size by Application (2015-2020)
7 EUROPE
7.1 Europe Central Nervous System Biomarkers Market Size (2015-2020)
7.2 Central Nervous System Biomarkers Key Players in Europe (2019-2020)
7.3 Europe Central Nervous System Biomarkers Market Size by Type (2015-2020)
7.4 Europe Central Nervous System Biomarkers Market Size by Application (2015-2020)
8 CHINA
8.1 China Central Nervous System Biomarkers Market Size (2015-2020)
8.2 Central Nervous System Biomarkers Key Players in China (2019-2020)
8.3 China Central Nervous System Biomarkers Market Size by Type (2015-2020)
8.4 China Central Nervous System Biomarkers Market Size by Application (2015-2020)
9 JAPAN
9.1 Japan Central Nervous System Biomarkers Market Size (2015-2020)
9.2 Central Nervous System Biomarkers Key Players in Japan (2019-2020)
9.3 Japan Central Nervous System Biomarkers Market Size by Type (2015-2020)
9.4 Japan Central Nervous System Biomarkers Market Size by Application (2015-2020)
10 SOUTHEAST ASIA
10.1 Southeast Asia Central Nervous System Biomarkers Market Size (2015-2020)
10.2 Central Nervous System Biomarkers Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Central Nervous System Biomarkers Market Size by Type (2015-2020)
10.4 Southeast Asia Central Nervous System Biomarkers Market Size by Application (2015-2020)
11 INDIA
11.1 India Central Nervous System Biomarkers Market Size (2015-2020)
11.2 Central Nervous System Biomarkers Key Players in India (2019-2020)
11.3 India Central Nervous System Biomarkers Market Size by Type (2015-2020)
11.4 India Central Nervous System Biomarkers Market Size by Application (2015-2020)
12 CENTRAL & SOUTH AMERICA
12.1 Central & South America Central Nervous System Biomarkers Market Size (2015-2020)
12.2 Central Nervous System Biomarkers Key Players in Central & South America (2019-2020)
12.3 Central & South America Central Nervous System Biomarkers Market Size by Type (2015-2020)
12.4 Central & South America Central Nervous System Biomarkers Market Size by Application (2015-2020)
13 KEY PLAYERS PROFILES
13.1 Merck
13.1.1 Merck Company Details
13.1.2 Merck Business Overview and Its Total Revenue
13.1.3 Merck Central Nervous System Biomarkers Introduction
13.1.4 Merck Revenue in Central Nervous System Biomarkers Business (2015-2020))
13.1.5 Merck Recent Development
13.2 Takeda Pharmaceutical
13.2.1 Takeda Pharmaceutical Company Details
13.2.2 Takeda Pharmaceutical Business Overview and Its Total Revenue
13.2.3 Takeda Pharmaceutical Central Nervous System Biomarkers Introduction
13.2.4 Takeda Pharmaceutical Revenue in Central Nervous System Biomarkers Business (2015-2020)
13.2.5 Takeda Pharmaceutical Recent Development
13.3 Thermo Fisher Scientific
13.3.1 Thermo Fisher Scientific Company Details
13.3.2 Thermo Fisher Scientific Business Overview and Its Total Revenue
13.3.3 Thermo Fisher Scientific Central Nervous System Biomarkers Introduction
13.3.4 Thermo Fisher Scientific Revenue in Central Nervous System Biomarkers Business (2015-2020)
13.3.5 Thermo Fisher Scientific Recent Development
13.4 Avacta Group
13.4.1 Avacta Group Company Details
13.4.2 Avacta Group Business Overview and Its Total Revenue
13.4.3 Avacta Group Central Nervous System Biomarkers Introduction
13.4.4 Avacta Group Revenue in Central Nervous System Biomarkers Business (2015-2020)
13.4.5 Avacta Group Recent Development
13.5 Diagenic Asa
13.5.1 Diagenic Asa Company Details
13.5.2 Diagenic Asa Business Overview and Its Total Revenue
13.5.3 Diagenic Asa Central Nervous System Biomarkers Introduction
13.5.4 Diagenic Asa Revenue in Central Nervous System Biomarkers Business (2015-2020)
13.5.5 Diagenic Asa Recent Development
13.6 Banyan Biomarkers
13.6.1 Banyan Biomarkers Company Details
13.6.2 Banyan Biomarkers Business Overview and Its Total Revenue
13.6.3 Banyan Biomarkers Central Nervous System Biomarkers Introduction
13.6.4 Banyan Biomarkers Revenue in Central Nervous System Biomarkers Business (2015-2020)
13.6.5 Banyan Biomarkers Recent Development
13.7 Eli Lilly
13.7.1 Eli Lilly Company Details
13.7.2 Eli Lilly Business Overview and Its Total Revenue
13.7.3 Eli Lilly Central Nervous System Biomarkers Introduction
13.7.4 Eli Lilly Revenue in Central Nervous System Biomarkers Business (2015-2020)
13.7.5 Eli Lilly Recent Development
13.8 Pfizer
13.8.1 Pfizer Company Details
13.8.2 Pfizer Business Overview and Its Total Revenue
13.8.3 Pfizer Central Nervous System Biomarkers Introduction
13.8.4 Pfizer Revenue in Central Nervous System Biomarkers Business (2015-2020)
13.8.5 Pfizer Recent Development
13.9 Alseres Pharmaceuticals
13.9.1 Alseres Pharmaceuticals Company Details
13.9.2 Alseres Pharmaceuticals Business Overview and Its Total Revenue
13.9.3 Alseres Pharmaceuticals Central Nervous System Biomarkers Introduction
13.9.4 Alseres Pharmaceuticals Revenue in Central Nervous System Biomarkers Business (2015-2020)
13.9.5 Alseres Pharmaceuticals Recent Development
13.10 Acumen pharmaceuticals
13.10.1 Acumen pharmaceuticals Company Details
13.10.2 Acumen pharmaceuticals Business Overview and Its Total Revenue
13.10.3 Acumen pharmaceuticals Central Nervous System Biomarkers Introduction
13.10.4 Acumen pharmaceuticals Revenue in Central Nervous System Biomarkers Business (2015-2020)
13.10.5 Acumen pharmaceuticals Recent Development
13.11 EKF Diagnostics
10.11.1 EKF Diagnostics Company Details
10.11.2 EKF Diagnostics Business Overview and Its Total Revenue
10.11.3 EKF Diagnostics Central Nervous System Biomarkers Introduction
10.11.4 EKF Diagnostics Revenue in Central Nervous System Biomarkers Business (2015-2020)
10.11.5 EKF Diagnostics Recent Development
13.12 Abiant
10.12.1 Abiant Company Details
10.12.2 Abiant Business Overview and Its Total Revenue
10.12.3 Abiant Central Nervous System Biomarkers Introduction
10.12.4 Abiant Revenue in Central Nervous System Biomarkers Business (2015-2020)
10.12.5 Abiant Recent Development
13.13 Myriad RBM
10.13.1 Myriad RBM Company Details
10.13.2 Myriad RBM Business Overview and Its Total Revenue
10.13.3 Myriad RBM Central Nervous System Biomarkers Introduction
10.13.4 Myriad RBM Revenue in Central Nervous System Biomarkers Business (2015-2020)
10.13.5 Myriad RBM Recent Development
13.14 Aposense
10.14.1 Aposense Company Details
10.14.2 Aposense Business Overview and Its Total Revenue
10.14.3 Aposense Central Nervous System Biomarkers Introduction
10.14.4 Aposense Revenue in Central Nervous System Biomarkers Business (2015-2020)
10.14.5 Aposense Recent Development
14 ANALYST'S VIEWPOINTS/CONCLUSIONS
15 APPENDIX
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
LIST OF TABLES
Table 1. Central Nervous System Biomarkers Key Market Segments
Table 2. Key Players Covered: Ranking by Central Nervous System Biomarkers Revenue
Table 3. Ranking of Global Top Central Nervous System Biomarkers Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Central Nervous System Biomarkers Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Safety Biomarker
Table 6. Key Players of Efficacy Biomarker
Table 7. Key Players of Validation Biomarker
Table 8. Key Players of Other
Table 9. COVID-19 Impact Global Market: (Four Central Nervous System Biomarkers Market Size Forecast Scenarios)
Table 10. Opportunities and Trends for Central Nervous System Biomarkers Players in the COVID-19 Landscape
Table 11. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 12. Key Regions/Countries Measures against Covid-19 Impact
Table 13. Proposal for Central Nervous System Biomarkers Players to Combat Covid-19 Impact
Table 14. Global Central Nervous System Biomarkers Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 15. Global Central Nervous System Biomarkers Market Size by Regions (US$ Million): 2020 VS 2026
Table 16. Global Central Nervous System Biomarkers Market Size by Regions (2015-2020) (US$ Million)
Table 17. Global Central Nervous System Biomarkers Market Share by Regions (2015-2020)
Table 18. Global Central Nervous System Biomarkers Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 19. Global Central Nervous System Biomarkers Market Share by Regions (2021-2026)
Table 20. Market Top Trends
Table 21. Key Drivers: Impact Analysis
Table 22. Key Challenges
Table 23. Central Nervous System Biomarkers Market Growth Strategy
Table 24. Main Points Interviewed from Key Central Nervous System Biomarkers Players
Table 25. Global Central Nervous System Biomarkers Revenue by Players (2015-2020) (Million US$)
Table 26. Global Central Nervous System Biomarkers Market Share by Players (2015-2020)
Table 27. Global Top Central Nervous System Biomarkers Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Central Nervous System Biomarkers as of 2019)
Table 28. Global Central Nervous System Biomarkers by Players Market Concentration Ratio (CR5 and HHI)
Table 29. Key Players Headquarters and Area Served
Table 30. Key Players Central Nervous System Biomarkers Product Solution and Service
Table 31. Date of Enter into Central Nervous System Biomarkers Market
Table 32. Mergers & Acquisitions, Expansion Plans
Table 33. Global Central Nervous System Biomarkers Market Size by Type (2015-2020) (Million US$)
Table 34. Global Central Nervous System Biomarkers Market Size Share by Type (2015-2020)
Table 35. Global Central Nervous System Biomarkers Revenue Market Share by Type (2021-2026)
Table 36. Global Central Nervous System Biomarkers Market Size Share by Application (2015-2020)
Table 37. Global Central Nervous System Biomarkers Market Size by Application (2015-2020) (Million US$)
Table 38. Global Central Nervous System Biomarkers Market Size Share by Application (2021-2026)
Table 39. North America Key Players Central Nervous System Biomarkers Revenue (2019-2020) (Million US$)
Table 40. North America Key Players Central Nervous System Biomarkers Market Share (2019-2020)
Table 41. North America Central Nervous System Biomarkers Market Size by Type (2015-2020) (Million US$)
Table 42. North America Central Nervous System Biomarkers Market Share by Type (2015-2020)
Table 43. North America Central Nervous System Biomarkers Market Size by Application (2015-2020) (Million US$)
Table 44. North America Central Nervous System Biomarkers Market Share by Application (2015-2020)
Table 45. Europe Key Players Central Nervous System Biomarkers Revenue (2019-2020) (Million US$)
Table 46. Europe Key Players Central Nervous System Biomarkers Market Share (2019-2020)
Table 47. Europe Central Nervous System Biomarkers Market Size by Type (2015-2020) (Million US$)
Table 48. Europe Central Nervous System Biomarkers Market Share by Type (2015-2020)
Table 49. Europe Central Nervous System Biomarkers Market Size by Application (2015-2020) (Million US$)
Table 50. Europe Central Nervous System Biomarkers Market Share by Application (2015-2020)
Table 51. China Key Players Central Nervous System Biomarkers Revenue (2019-2020) (Million US$)
Table 52. China Key Players Central Nervous System Biomarkers Market Share (2019-2020)
Table 53. China Central Nervous System Biomarkers Market Size by Type (2015-2020) (Million US$)
Table 54. China Central Nervous System Biomarkers Market Share by Type (2015-2020)
Table 55. China Central Nervous System Biomarkers Market Size by Application (2015-2020) (Million US$)
Table 56. China Central Nervous System Biomarkers Market Share by Application (2015-2020)
Table 57. Japan Key Players Central Nervous System Biomarkers Revenue (2019-2020) (Million US$)
Table 58. Japan Key Players Central Nervous System Biomarkers Market Share (2019-2020)
Table 59. Japan Central Nervous System Biomarkers Market Size by Type (2015-2020) (Million US$)
Table 60. Japan Central Nervous System Biomarkers Market Share by Type (2015-2020)
Table 61. Japan Central Nervous System Biomarkers Market Size by Application (2015-2020) (Million US$)
Table 62. Japan Central Nervous System Biomarkers Market Share by Application (2015-2020)
Table 63. Southeast Asia Key Players Central Nervous System Biomarkers Revenue (2019-2020) (Million US$)
Table 64. Southeast Asia Key Players Central Nervous System Biomarkers Market Share (2019-2020)
Table 65. Southeast Asia Central Nervous System Biomarkers Market Size by Type (2015-2020) (Million US$)
Table 66. Southeast Asia Central Nervous System Biomarkers Market Share by Type (2015-2020)
Table 67. Southeast Asia Central Nervous System Biomarkers Market Size by Application (2015-2020) (Million US$)
Table 68. Southeast Asia Central Nervous System Biomarkers Market Share by Application (2015-2020)
Table 69. India Key Players Central Nervous System Biomarkers Revenue (2019-2020) (Million US$)
Table 70. India Key Players Central Nervous System Biomarkers Market Share (2019-2020)
Table 71. India Central Nervous System Biomarkers Market Size by Type (2015-2020) (Million US$)
Table 72. India Central Nervous System Biomarkers Market Share by Type (2015-2020)
Table 73. India Central Nervous System Biomarkers Market Size by Application (2015-2020) (Million US$)
Table 74. India Central Nervous System Biomarkers Market Share by Application (2015-2020)
Table 75. Central & South America Key Players Central Nervous System Biomarkers Revenue (2019-2020) (Million US$)
Table 76. Central & South America Key Players Central Nervous System Biomarkers Market Share (2019-2020)
Table 77. Central & South America Central Nervous System Biomarkers Market Size by Type (2015-2020) (Million US$)
Table 78. Central & South America Central Nervous System Biomarkers Market Share by Type (2015-2020)
Table 79. Central & South America Central Nervous System Biomarkers Market Size by Application (2015-2020) (Million US$)
Table 80. Central & South America Central Nervous System Biomarkers Market Share by Application (2015-2020)
Table 81. Merck Company Details
Table 82. Merck Business Overview
Table 83. Merck Product
Table 84. Merck Revenue in Central Nervous System Biomarkers Business (2015-2020) (Million US$)
Table 85. Merck Recent Development
Table 86. Takeda Pharmaceutical Company Details
Table 87. Takeda Pharmaceutical Business Overview
Table 88. Takeda Pharmaceutical Product
Table 89. Takeda Pharmaceutical Revenue in Central Nervous System Biomarkers Business (2015-2020) (Million US$)
Table 90. Takeda Pharmaceutical Recent Development
Table 91. Thermo Fisher Scientific Company Details
Table 92. Thermo Fisher Scientific Business Overview
Table 93. Thermo Fisher Scientific Product
Table 94. Thermo Fisher Scientific Revenue in Central Nervous System Biomarkers Business (2015-2020) (Million US$)
Table 95. Thermo Fisher Scientific Recent Development
Table 96. Avacta Group Company Details
Table 97. Avacta Group Business Overview
Table 98. Avacta Group Product
Table 99. Avacta Group Revenue in Central Nervous System Biomarkers Business (2015-2020) (Million US$)
Table 100. Avacta Group Recent Development
Table 101. Diagenic Asa Company Details
Table 102. Diagenic Asa Business Overview
Table 103. Diagenic Asa Product
Table 104. Diagenic Asa Revenue in Central Nervous System Biomarkers Business (2015-2020) (Million US$)
Table 105. Diagenic Asa Recent Development
Table 106. Banyan Biomarkers Company Details
Table 107. Banyan Biomarkers Business Overview
Table 108. Banyan Biomarkers Product
Table 109. Banyan Biomarkers Revenue in Central Nervous System Biomarkers Business (2015-2020) (Million US$)
Table 110. Banyan Biomarkers Recent Development
Table 111. Eli Lilly Company Details
Table 112. Eli Lilly Business Overview
Table 113. Eli Lilly Product
Table 114. Eli Lilly Revenue in Central Nervous System Biomarkers Business (2015-2020) (Million US$)
Table 115. Eli Lilly Recent Development
Table 116. Pfizer Business Overview
Table 117. Pfizer Product
Table 118. Pfizer Company Details
Table 119. Pfizer Revenue in Central Nervous System Biomarkers Business (2015-2020) (Million US$)
Table 120. Pfizer Recent Development
Table 121. Alseres Pharmaceuticals Company Details
Table 122. Alseres Pharmaceuticals Business Overview
Table 123. Alseres Pharmaceuticals Product
Table 124. Alseres Pharmaceuticals Revenue in Central Nervous System Biomarkers Business (2015-2020) (Million US$)
Table 125. Alseres Pharmaceuticals Recent Development
Table 126. Acumen pharmaceuticals Company Details
Table 127. Acumen pharmaceuticals Business Overview
Table 128. Acumen pharmaceuticals Product
Table 129. Acumen pharmaceuticals Revenue in Central Nervous System Biomarkers Business (2015-2020) (Million US$)
Table 130. Acumen pharmaceuticals Recent Development
Table 131. EKF Diagnostics Company Details
Table 132. EKF Diagnostics Business Overview
Table 133. EKF Diagnostics Product
Table 134. EKF Diagnostics Revenue in Central Nervous System Biomarkers Business (2015-2020) (Million US$)
Table 135. EKF Diagnostics Recent Development
Table 136. Abiant Company Details
Table 137. Abiant Business Overview
Table 138. Abiant Product
Table 139. Abiant Revenue in Central Nervous System Biomarkers Business (2015-2020) (Million US$)
Table 140. Abiant Recent Development
Table 141. Myriad RBM Company Details
Table 142. Myriad RBM Business Overview
Table 143. Myriad RBM Product
Table 144. Myriad RBM Revenue in Central Nervous System Biomarkers Business (2015-2020) (Million US$)
Table 145. Myriad RBM Recent Development
Table 146. Aposense Company Details
Table 147. Aposense Business Overview
Table 148. Aposense Product
Table 149. Aposense Revenue in Central Nervous System Biomarkers Business (2015-2020) (Million US$)
Table 150. Aposense Recent Development
Table 151. Research Programs/Design for This Report
Table 152. Key Data Information from Secondary Sources
Table 153. Key Data Information from Primary Sources
Table 1. Central Nervous System Biomarkers Key Market Segments
Table 2. Key Players Covered: Ranking by Central Nervous System Biomarkers Revenue
Table 3. Ranking of Global Top Central Nervous System Biomarkers Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Central Nervous System Biomarkers Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Safety Biomarker
Table 6. Key Players of Efficacy Biomarker
Table 7. Key Players of Validation Biomarker
Table 8. Key Players of Other
Table 9. COVID-19 Impact Global Market: (Four Central Nervous System Biomarkers Market Size Forecast Scenarios)
Table 10. Opportunities and Trends for Central Nervous System Biomarkers Players in the COVID-19 Landscape
Table 11. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis
Table 12. Key Regions/Countries Measures against Covid-19 Impact
Table 13. Proposal for Central Nervous System Biomarkers Players to Combat Covid-19 Impact
Table 14. Global Central Nervous System Biomarkers Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 15. Global Central Nervous System Biomarkers Market Size by Regions (US$ Million): 2020 VS 2026
Table 16. Global Central Nervous System Biomarkers Market Size by Regions (2015-2020) (US$ Million)
Table 17. Global Central Nervous System Biomarkers Market Share by Regions (2015-2020)
Table 18. Global Central Nervous System Biomarkers Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 19. Global Central Nervous System Biomarkers Market Share by Regions (2021-2026)
Table 20. Market Top Trends
Table 21. Key Drivers: Impact Analysis
Table 22. Key Challenges
Table 23. Central Nervous System Biomarkers Market Growth Strategy
Table 24. Main Points Interviewed from Key Central Nervous System Biomarkers Players
Table 25. Global Central Nervous System Biomarkers Revenue by Players (2015-2020) (Million US$)
Table 26. Global Central Nervous System Biomarkers Market Share by Players (2015-2020)
Table 27. Global Top Central Nervous System Biomarkers Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Central Nervous System Biomarkers as of 2019)
Table 28. Global Central Nervous System Biomarkers by Players Market Concentration Ratio (CR5 and HHI)
Table 29. Key Players Headquarters and Area Served
Table 30. Key Players Central Nervous System Biomarkers Product Solution and Service
Table 31. Date of Enter into Central Nervous System Biomarkers Market
Table 32. Mergers & Acquisitions, Expansion Plans
Table 33. Global Central Nervous System Biomarkers Market Size by Type (2015-2020) (Million US$)
Table 34. Global Central Nervous System Biomarkers Market Size Share by Type (2015-2020)
Table 35. Global Central Nervous System Biomarkers Revenue Market Share by Type (2021-2026)
Table 36. Global Central Nervous System Biomarkers Market Size Share by Application (2015-2020)
Table 37. Global Central Nervous System Biomarkers Market Size by Application (2015-2020) (Million US$)
Table 38. Global Central Nervous System Biomarkers Market Size Share by Application (2021-2026)
Table 39. North America Key Players Central Nervous System Biomarkers Revenue (2019-2020) (Million US$)
Table 40. North America Key Players Central Nervous System Biomarkers Market Share (2019-2020)
Table 41. North America Central Nervous System Biomarkers Market Size by Type (2015-2020) (Million US$)
Table 42. North America Central Nervous System Biomarkers Market Share by Type (2015-2020)
Table 43. North America Central Nervous System Biomarkers Market Size by Application (2015-2020) (Million US$)
Table 44. North America Central Nervous System Biomarkers Market Share by Application (2015-2020)
Table 45. Europe Key Players Central Nervous System Biomarkers Revenue (2019-2020) (Million US$)
Table 46. Europe Key Players Central Nervous System Biomarkers Market Share (2019-2020)
Table 47. Europe Central Nervous System Biomarkers Market Size by Type (2015-2020) (Million US$)
Table 48. Europe Central Nervous System Biomarkers Market Share by Type (2015-2020)
Table 49. Europe Central Nervous System Biomarkers Market Size by Application (2015-2020) (Million US$)
Table 50. Europe Central Nervous System Biomarkers Market Share by Application (2015-2020)
Table 51. China Key Players Central Nervous System Biomarkers Revenue (2019-2020) (Million US$)
Table 52. China Key Players Central Nervous System Biomarkers Market Share (2019-2020)
Table 53. China Central Nervous System Biomarkers Market Size by Type (2015-2020) (Million US$)
Table 54. China Central Nervous System Biomarkers Market Share by Type (2015-2020)
Table 55. China Central Nervous System Biomarkers Market Size by Application (2015-2020) (Million US$)
Table 56. China Central Nervous System Biomarkers Market Share by Application (2015-2020)
Table 57. Japan Key Players Central Nervous System Biomarkers Revenue (2019-2020) (Million US$)
Table 58. Japan Key Players Central Nervous System Biomarkers Market Share (2019-2020)
Table 59. Japan Central Nervous System Biomarkers Market Size by Type (2015-2020) (Million US$)
Table 60. Japan Central Nervous System Biomarkers Market Share by Type (2015-2020)
Table 61. Japan Central Nervous System Biomarkers Market Size by Application (2015-2020) (Million US$)
Table 62. Japan Central Nervous System Biomarkers Market Share by Application (2015-2020)
Table 63. Southeast Asia Key Players Central Nervous System Biomarkers Revenue (2019-2020) (Million US$)
Table 64. Southeast Asia Key Players Central Nervous System Biomarkers Market Share (2019-2020)
Table 65. Southeast Asia Central Nervous System Biomarkers Market Size by Type (2015-2020) (Million US$)
Table 66. Southeast Asia Central Nervous System Biomarkers Market Share by Type (2015-2020)
Table 67. Southeast Asia Central Nervous System Biomarkers Market Size by Application (2015-2020) (Million US$)
Table 68. Southeast Asia Central Nervous System Biomarkers Market Share by Application (2015-2020)
Table 69. India Key Players Central Nervous System Biomarkers Revenue (2019-2020) (Million US$)
Table 70. India Key Players Central Nervous System Biomarkers Market Share (2019-2020)
Table 71. India Central Nervous System Biomarkers Market Size by Type (2015-2020) (Million US$)
Table 72. India Central Nervous System Biomarkers Market Share by Type (2015-2020)
Table 73. India Central Nervous System Biomarkers Market Size by Application (2015-2020) (Million US$)
Table 74. India Central Nervous System Biomarkers Market Share by Application (2015-2020)
Table 75. Central & South America Key Players Central Nervous System Biomarkers Revenue (2019-2020) (Million US$)
Table 76. Central & South America Key Players Central Nervous System Biomarkers Market Share (2019-2020)
Table 77. Central & South America Central Nervous System Biomarkers Market Size by Type (2015-2020) (Million US$)
Table 78. Central & South America Central Nervous System Biomarkers Market Share by Type (2015-2020)
Table 79. Central & South America Central Nervous System Biomarkers Market Size by Application (2015-2020) (Million US$)
Table 80. Central & South America Central Nervous System Biomarkers Market Share by Application (2015-2020)
Table 81. Merck Company Details
Table 82. Merck Business Overview
Table 83. Merck Product
Table 84. Merck Revenue in Central Nervous System Biomarkers Business (2015-2020) (Million US$)
Table 85. Merck Recent Development
Table 86. Takeda Pharmaceutical Company Details
Table 87. Takeda Pharmaceutical Business Overview
Table 88. Takeda Pharmaceutical Product
Table 89. Takeda Pharmaceutical Revenue in Central Nervous System Biomarkers Business (2015-2020) (Million US$)
Table 90. Takeda Pharmaceutical Recent Development
Table 91. Thermo Fisher Scientific Company Details
Table 92. Thermo Fisher Scientific Business Overview
Table 93. Thermo Fisher Scientific Product
Table 94. Thermo Fisher Scientific Revenue in Central Nervous System Biomarkers Business (2015-2020) (Million US$)
Table 95. Thermo Fisher Scientific Recent Development
Table 96. Avacta Group Company Details
Table 97. Avacta Group Business Overview
Table 98. Avacta Group Product
Table 99. Avacta Group Revenue in Central Nervous System Biomarkers Business (2015-2020) (Million US$)
Table 100. Avacta Group Recent Development
Table 101. Diagenic Asa Company Details
Table 102. Diagenic Asa Business Overview
Table 103. Diagenic Asa Product
Table 104. Diagenic Asa Revenue in Central Nervous System Biomarkers Business (2015-2020) (Million US$)
Table 105. Diagenic Asa Recent Development
Table 106. Banyan Biomarkers Company Details
Table 107. Banyan Biomarkers Business Overview
Table 108. Banyan Biomarkers Product
Table 109. Banyan Biomarkers Revenue in Central Nervous System Biomarkers Business (2015-2020) (Million US$)
Table 110. Banyan Biomarkers Recent Development
Table 111. Eli Lilly Company Details
Table 112. Eli Lilly Business Overview
Table 113. Eli Lilly Product
Table 114. Eli Lilly Revenue in Central Nervous System Biomarkers Business (2015-2020) (Million US$)
Table 115. Eli Lilly Recent Development
Table 116. Pfizer Business Overview
Table 117. Pfizer Product
Table 118. Pfizer Company Details
Table 119. Pfizer Revenue in Central Nervous System Biomarkers Business (2015-2020) (Million US$)
Table 120. Pfizer Recent Development
Table 121. Alseres Pharmaceuticals Company Details
Table 122. Alseres Pharmaceuticals Business Overview
Table 123. Alseres Pharmaceuticals Product
Table 124. Alseres Pharmaceuticals Revenue in Central Nervous System Biomarkers Business (2015-2020) (Million US$)
Table 125. Alseres Pharmaceuticals Recent Development
Table 126. Acumen pharmaceuticals Company Details
Table 127. Acumen pharmaceuticals Business Overview
Table 128. Acumen pharmaceuticals Product
Table 129. Acumen pharmaceuticals Revenue in Central Nervous System Biomarkers Business (2015-2020) (Million US$)
Table 130. Acumen pharmaceuticals Recent Development
Table 131. EKF Diagnostics Company Details
Table 132. EKF Diagnostics Business Overview
Table 133. EKF Diagnostics Product
Table 134. EKF Diagnostics Revenue in Central Nervous System Biomarkers Business (2015-2020) (Million US$)
Table 135. EKF Diagnostics Recent Development
Table 136. Abiant Company Details
Table 137. Abiant Business Overview
Table 138. Abiant Product
Table 139. Abiant Revenue in Central Nervous System Biomarkers Business (2015-2020) (Million US$)
Table 140. Abiant Recent Development
Table 141. Myriad RBM Company Details
Table 142. Myriad RBM Business Overview
Table 143. Myriad RBM Product
Table 144. Myriad RBM Revenue in Central Nervous System Biomarkers Business (2015-2020) (Million US$)
Table 145. Myriad RBM Recent Development
Table 146. Aposense Company Details
Table 147. Aposense Business Overview
Table 148. Aposense Product
Table 149. Aposense Revenue in Central Nervous System Biomarkers Business (2015-2020) (Million US$)
Table 150. Aposense Recent Development
Table 151. Research Programs/Design for This Report
Table 152. Key Data Information from Secondary Sources
Table 153. Key Data Information from Primary Sources
LIST OF FIGURES
Figure 1. Global Central Nervous System Biomarkers Market Share by Type: 2020 VS 2026
Figure 2. Safety Biomarker Features
Figure 3. Efficacy Biomarker Features
Figure 4. Validation Biomarker Features
Figure 5. Other Features
Figure 6. Global Central Nervous System Biomarkers Market Share by Application: 2020 VS 2026
Figure 7. Hospitals Case Studies
Figure 8. Clinics Case Studies
Figure 9. Others Case Studies
Figure 10. Central Nervous System Biomarkers Report Years Considered
Figure 11. Global Central Nervous System Biomarkers Market Size YoY Growth 2015-2026 (US$ Million)
Figure 12. Global Central Nervous System Biomarkers Market Share by Regions: 2020 VS 2026
Figure 13. Global Central Nervous System Biomarkers Market Share by Regions (2021-2026)
Figure 14. Porter's Five Forces Analysis
Figure 15. Global Central Nervous System Biomarkers Market Share by Players in 2019
Figure 16. Global Top Central Nervous System Biomarkers Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Central Nervous System Biomarkers as of 2019
Figure 17. The Top 10 and 5 Players Market Share by Central Nervous System Biomarkers Revenue in 2019
Figure 18. North America Central Nervous System Biomarkers Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. Europe Central Nervous System Biomarkers Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. China Central Nervous System Biomarkers Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Japan Central Nervous System Biomarkers Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Southeast Asia Central Nervous System Biomarkers Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. India Central Nervous System Biomarkers Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Central & South America Central Nervous System Biomarkers Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Merck Total Revenue (US$ Million): 2019 Compared with 2018
Figure 26. Merck Revenue Growth Rate in Central Nervous System Biomarkers Business (2015-2020)
Figure 27. Takeda Pharmaceutical Total Revenue (US$ Million): 2019 Compared with 2018
Figure 28. Takeda Pharmaceutical Revenue Growth Rate in Central Nervous System Biomarkers Business (2015-2020)
Figure 29. Thermo Fisher Scientific Total Revenue (US$ Million): 2019 Compared with 2018
Figure 30. Thermo Fisher Scientific Revenue Growth Rate in Central Nervous System Biomarkers Business (2015-2020)
Figure 31. Avacta Group Total Revenue (US$ Million): 2019 Compared with 2018
Figure 32. Avacta Group Revenue Growth Rate in Central Nervous System Biomarkers Business (2015-2020)
Figure 33. Diagenic Asa Total Revenue (US$ Million): 2019 Compared with 2018
Figure 34. Diagenic Asa Revenue Growth Rate in Central Nervous System Biomarkers Business (2015-2020)
Figure 35. Banyan Biomarkers Total Revenue (US$ Million): 2019 Compared with 2018
Figure 36. Banyan Biomarkers Revenue Growth Rate in Central Nervous System Biomarkers Business (2015-2020)
Figure 37. Eli Lilly Total Revenue (US$ Million): 2019 Compared with 2018
Figure 38. Eli Lilly Revenue Growth Rate in Central Nervous System Biomarkers Business (2015-2020)
Figure 39. Pfizer Total Revenue (US$ Million): 2019 Compared with 2018
Figure 40. Pfizer Revenue Growth Rate in Central Nervous System Biomarkers Business (2015-2020)
Figure 41. Alseres Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 42. Alseres Pharmaceuticals Revenue Growth Rate in Central Nervous System Biomarkers Business (2015-2020)
Figure 43. Acumen pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 44. Acumen pharmaceuticals Revenue Growth Rate in Central Nervous System Biomarkers Business (2015-2020)
Figure 45. EKF Diagnostics Total Revenue (US$ Million): 2019 Compared with 2018
Figure 46. EKF Diagnostics Revenue Growth Rate in Central Nervous System Biomarkers Business (2015-2020)
Figure 47. Abiant Total Revenue (US$ Million): 2019 Compared with 2018
Figure 48. Abiant Revenue Growth Rate in Central Nervous System Biomarkers Business (2015-2020)
Figure 49. Myriad RBM Total Revenue (US$ Million): 2019 Compared with 2018
Figure 50. Myriad RBM Revenue Growth Rate in Central Nervous System Biomarkers Business (2015-2020)
Figure 51. Aposense Total Revenue (US$ Million): 2019 Compared with 2018
Figure 52. Aposense Revenue Growth Rate in Central Nervous System Biomarkers Business (2015-2020)
Figure 53. Bottom-up and Top-down Approaches for This Report
Figure 54. Data Triangulation
Figure 55. Key Executives Interviewed
Figure 1. Global Central Nervous System Biomarkers Market Share by Type: 2020 VS 2026
Figure 2. Safety Biomarker Features
Figure 3. Efficacy Biomarker Features
Figure 4. Validation Biomarker Features
Figure 5. Other Features
Figure 6. Global Central Nervous System Biomarkers Market Share by Application: 2020 VS 2026
Figure 7. Hospitals Case Studies
Figure 8. Clinics Case Studies
Figure 9. Others Case Studies
Figure 10. Central Nervous System Biomarkers Report Years Considered
Figure 11. Global Central Nervous System Biomarkers Market Size YoY Growth 2015-2026 (US$ Million)
Figure 12. Global Central Nervous System Biomarkers Market Share by Regions: 2020 VS 2026
Figure 13. Global Central Nervous System Biomarkers Market Share by Regions (2021-2026)
Figure 14. Porter's Five Forces Analysis
Figure 15. Global Central Nervous System Biomarkers Market Share by Players in 2019
Figure 16. Global Top Central Nervous System Biomarkers Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Central Nervous System Biomarkers as of 2019
Figure 17. The Top 10 and 5 Players Market Share by Central Nervous System Biomarkers Revenue in 2019
Figure 18. North America Central Nervous System Biomarkers Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. Europe Central Nervous System Biomarkers Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. China Central Nervous System Biomarkers Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Japan Central Nervous System Biomarkers Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. Southeast Asia Central Nervous System Biomarkers Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. India Central Nervous System Biomarkers Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Central & South America Central Nervous System Biomarkers Market Size YoY Growth (2015-2020) (Million US$)
Figure 25. Merck Total Revenue (US$ Million): 2019 Compared with 2018
Figure 26. Merck Revenue Growth Rate in Central Nervous System Biomarkers Business (2015-2020)
Figure 27. Takeda Pharmaceutical Total Revenue (US$ Million): 2019 Compared with 2018
Figure 28. Takeda Pharmaceutical Revenue Growth Rate in Central Nervous System Biomarkers Business (2015-2020)
Figure 29. Thermo Fisher Scientific Total Revenue (US$ Million): 2019 Compared with 2018
Figure 30. Thermo Fisher Scientific Revenue Growth Rate in Central Nervous System Biomarkers Business (2015-2020)
Figure 31. Avacta Group Total Revenue (US$ Million): 2019 Compared with 2018
Figure 32. Avacta Group Revenue Growth Rate in Central Nervous System Biomarkers Business (2015-2020)
Figure 33. Diagenic Asa Total Revenue (US$ Million): 2019 Compared with 2018
Figure 34. Diagenic Asa Revenue Growth Rate in Central Nervous System Biomarkers Business (2015-2020)
Figure 35. Banyan Biomarkers Total Revenue (US$ Million): 2019 Compared with 2018
Figure 36. Banyan Biomarkers Revenue Growth Rate in Central Nervous System Biomarkers Business (2015-2020)
Figure 37. Eli Lilly Total Revenue (US$ Million): 2019 Compared with 2018
Figure 38. Eli Lilly Revenue Growth Rate in Central Nervous System Biomarkers Business (2015-2020)
Figure 39. Pfizer Total Revenue (US$ Million): 2019 Compared with 2018
Figure 40. Pfizer Revenue Growth Rate in Central Nervous System Biomarkers Business (2015-2020)
Figure 41. Alseres Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 42. Alseres Pharmaceuticals Revenue Growth Rate in Central Nervous System Biomarkers Business (2015-2020)
Figure 43. Acumen pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 44. Acumen pharmaceuticals Revenue Growth Rate in Central Nervous System Biomarkers Business (2015-2020)
Figure 45. EKF Diagnostics Total Revenue (US$ Million): 2019 Compared with 2018
Figure 46. EKF Diagnostics Revenue Growth Rate in Central Nervous System Biomarkers Business (2015-2020)
Figure 47. Abiant Total Revenue (US$ Million): 2019 Compared with 2018
Figure 48. Abiant Revenue Growth Rate in Central Nervous System Biomarkers Business (2015-2020)
Figure 49. Myriad RBM Total Revenue (US$ Million): 2019 Compared with 2018
Figure 50. Myriad RBM Revenue Growth Rate in Central Nervous System Biomarkers Business (2015-2020)
Figure 51. Aposense Total Revenue (US$ Million): 2019 Compared with 2018
Figure 52. Aposense Revenue Growth Rate in Central Nervous System Biomarkers Business (2015-2020)
Figure 53. Bottom-up and Top-down Approaches for This Report
Figure 54. Data Triangulation
Figure 55. Key Executives Interviewed